# Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction

Study · id `cardio:ct-nct01499407` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01499407](<https://clinicaltrials.gov/study/NCT01499407>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01499407

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 128 participants.

## Technical summary

Registry record NCT01499407. Randomized; double masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2012-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 128 participants (planned count; ClinicalTrials.gov record NCT01499407, source copy `cardio:ctgov-nct01499407-2012-01-05`, retrieved 2026-10-26)
- Start date: 2011-12 (registry gives no type) (ClinicalTrials.gov record NCT01499407, source copy `cardio:ctgov-nct01499407-2012-01-05`, retrieved 2026-10-26)
- Primary completion: 2012-12 (anticipated) (ClinicalTrials.gov record NCT01499407, source copy `cardio:ctgov-nct01499407-2012-01-05`, retrieved 2026-10-26)
- Completion: 2013-04 (anticipated) (ClinicalTrials.gov record NCT01499407, source copy `cardio:ctgov-nct01499407-2012-01-05`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT01499407, source copy `cardio:ctgov-nct01499407-2012-01-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01499407-2012-01-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction
- Acronym: COCTAIL II
- Condition: ST-elevation Myocardial Infarction
- Intervention (Device): ClearWay RX catheter
- Intervention (Drug): Abciximab
- Lead sponsor: CLI Foundation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)

## Provenance

Content hash: e44150849a592aa4beb353865f95444d6047b097635e51af42287a5e8f743027
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
